EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19

Karol Biernacki, Olga Ciupak, Mateusz Daśko, Janusz Rachon, Damian Flis, Justyna Budka, Iwona Inkielewicz-Stępniak, Anna Czaja, Janusz Rak, Sebastian Demkowicz

Journal of Enzyme Inhibition and Medicinal Chemistry · 2024

DOI: 10.1080/14756366.2023.2290910 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2024. Verfasst von Karol Biernacki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organic Chemistry, Gdańsk University of Technology, Gdańsk, Poland. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gdańsk University of Technology for: ‘Excellence Initiative - Research University’ (IDUB) program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the present work, we report a new series of potent SARS-CoV-2 Main Protease (Mpro) inhibitors based on maleimide derivatives. The inhibitory activities were tested in an enzymatic assay using recombinant Mpro (3CL Protease from coronavirus SARS-CoV-2). Within the set of new Mpro inhibitors, 6e demonstrated the highest activity in the enzymatic assay with an IC50 value of 8.52 ± 0.44 µM. The IC50 value for Nirmatrelvir (PF-07321332, used as a reference) was 0.84 ± 0.37 µM. The cytotoxic properties were determined in the MTT assay using MRC-5 and HEK-293 cell lines. In the course of the investigation, we found that the newly obtained maleimide derivatives are not substantially cytotoxic (IC50 values for most compounds were above 200 µM).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansHEK293 CellsSARS-CoV-2MaleimidesLactamsLeucineNitrilesProtease InhibitorsMolecular Docking SimulationAntiviral AgentsCoronavirus 3C Proteases

Stichwörter der Autor:innen

COVID-19Coronavirus SARS-CoV-2SARS-CoV-2 main protease mpro inhibitorsmaleimide derivatives

Substanzen

MaleimidesLactamsLeucineNitrilesProtease InhibitorsAntiviral Agents3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteasesmaleimide

Autor:innen und Institutionen

  • Department of Organic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
  • Department of Inorganic Chemistry, Gdańsk University of Technology, Gdańsk, Poland.
  • Department of Pharmaceutical Pathophysiology, Medical University of Gdansk, Gdańsk, Poland.
  • Department of Physical Chemistry, University of Gdańsk, Gdańsk, Poland.

Förderung

  • Gdańsk University of Technology for: ‘Excellence Initiative - Research University’ (IDUB) program

Zitieren

APA

Biernacki, K., Ciupak, O., Daśko, M., Rachon, J., Flis, D., Budka, J., Inkielewicz-Stępniak, I., Czaja, A., Rak, J., & Demkowicz, S. (2024). Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2290910

Vancouver

Biernacki K, Ciupak O, Daśko M, Rachon J, Flis D, Budka J, et al. Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19. Journal of Enzyme Inhibition and Medicinal Chemistry. 2024. doi:10.1080/14756366.2023.2290910

BibTeX
@article{Biernacki2024,
  author = {Biernacki, Karol and Ciupak, Olga and Daśko, Mateusz and Rachon, Janusz and Flis, Damian and Budka, Justyna and Inkielewicz-Stępniak, Iwona and Czaja, Anna and Rak, Janusz and Demkowicz, Sebastian},
  title = {Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2024},
  doi = {10.1080/14756366.2023.2290910}
}
Kostenlos starten →